Germany's Merck KGaA to Acquire Bio-Techne in $11.3 Billion Life Sciences Mega-Deal
核心洞察
Merck KGaA announced a definitive agreement to acquire U.S. biotech firm Bio-Techne (搜索) for $11.3 billion, representing a 24% premium at $73 per share.
The deal is Merck's largest acquisition since the $17 billion Sigma-Aldrich (搜索) purchase in 2014 and the first major move under new CEO Kai Beckmann.
Bio-Techne (搜索) brings a portfolio of 6,000 proteins, 425,000 antibodies, reagents, analytical instruments, and services that strengthen Merck's cell and gene therapy capabilities.
German drugmaker Merck KGaA announced on Thursday that it will acquire Minneapolis-based life-science tools supplier Bio-Techne (搜索) in a transaction valued at $11.3 billion, marking the company's largest deal in over a decade and the first major acquisition under newly appointed CEO Kai Beckmann.
Under the terms of the agreement, Merck will pay $73 per share in cash for Bio-Techne (搜索), representing a 24% premium to the company's closing price on Wednesday. Shares of Bio-Techne surged 20% to $70.61 in premarket trading following the announcement, while Merck KGaA shares rose between 0.5% and 3% in European trading.
The acquisition will be funded through a combination of existing cash and new debt. Merck reported cash and cash equivalents of approximately €2.74 billion ($3.11 billion) in its latest quarterly results.
Strategic Rationale and Portfolio Expansion
The deal significantly expands Merck's footprint in advanced biological research and cell and gene therapy, reinforcing its life sciences business as the primary growth driver for the company. Bio-Techne (搜索) supplies research reagents, proteins, antibodies, analytical instruments, and other tools widely used by scientists and drug developers.
Merck's Life Science CEO Jean-Charles Wirth emphasized the scale Bio-Techne (搜索) brings, highlighting its catalog of 6,000 proteins and 425,000 antibodies as a "big, big plus" for customers.
The transaction follows a series of acquisitions under former CEO Belén Garijo, including Exelead (搜索), Mirus Bio (搜索), and SpringWorks Therapeutics, which strengthened Merck's positions in mRNA manufacturing, cell and gene therapy, and rare diseases. Last year, Garijo stated the group had an "appetite for M&A" with a priority on life sciences.
Leadership Transition and Market Context
Kai Beckmann, who took over as CEO in May from Belén Garijo, recently signaled that acquisitions would be a key growth driver for all businesses of the group, which spans pharmaceuticals, life-sciences equipment, and materials for semiconductors and electronic devices. The Bio-Techne (搜索) acquisition appears consistent with Garijo's strategy of prioritizing life sciences investments.
The deal arrives at a time when life-sciences tools suppliers are positioning themselves to capture heavy investments by pharmaceutical companies in research and development, alongside a recovery in biotech funding that had been constrained when central banks raised interest rates following the Covid-19 pandemic. Major U.S. competitors Thermo Fisher Scientific (搜索) and Danaher (搜索) have also completed multibillion-dollar acquisitions over the past year.
Financial Details and Timeline
The Bio-Techne (搜索) acquisition is Merck's largest life sciences deal since its $17 billion purchase of Sigma-Aldrich (搜索) in 2014, which strengthened its research tools business and diversification beyond pharmaceuticals.
Bio-Techne (搜索) Chairman Robert V. Baumgartner said a thorough review led the board to conclude that the deal delivered substantial, near-term value to its shareholders.
The transaction is subject to regulatory authorizations and approval by Bio-Techne (搜索) shareholders. Merck expects the deal to close by late 2026 or early 2027, with cost savings of approximately €140 million to be fully realized by the third year after closing.
Some analysts noted the transaction was a strategic fit and that they did not anticipate significant regulatory hurdles. Leerink analyst Puneet Souda commented that Merck appears to be acquiring an attractive asset with strong long-term potential, despite current pressures in the research tools market.